3x5 News

 

Wall Street Journal

3x5 is a rare sustainability-focused firm with strong returns

After years of building a well-performing portfolio of sustainability and life sciences companies, 3x5 Partners is expanding through new fundraising and a larger team.


Allakos_new.jpg

Allakos Announces Upsizing and Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 06, 2019 Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the upsizing and pricing of its previously announced underwritten public offering. The size of the offering has been increased from the previously announced $200 million of shares of the Company’s common stock to $350 million of shares of its common stock.

Tech+Photo+2.jpg

Forbes Names Rubicon Global One of Next Billion Dollar Startups

ATLANTA, Oct. 20, 2016 (GLOBE NEWSWIRE) — Rubicon Global, the worldwide leader in sustainable, cloud-based waste and recycling solutions, has been named to Forbes’ list of the Next Billion Dollar Startups. “Rubicon Global is using the free market to help solve the world’s oldest environmental problem while also saving money for our customers,” said Nate Morris, founder and CEO of Rubicon.


AZ.jpg
wp1.jpg

AstraZeneca to Buy ZS Pharma for $2.7 Billion Deal will bolster drug maker’s cardiovascular disease portfolio

LONDON—AstraZeneca PLC has agreed to pay $2.7 billion for Californian biotech ZS Pharma Inc., in a deal which will bolster the drug maker’s cardiovascular disease portfolio as it faces the loss of exclusivity in the U.S. for its best-selling cholesterol-lowering drug Crestor.

Smart Wires and Hunt Energy Solutions Announce Distribution Partnership in Latin America

Smart Wires and Hunt Energy Solutions are pleased to announce their formal partnership whereby Hunt Energy Solutions will serve as Smart Wires’ exclusive distribution partner in the Latin American areas of Mexico, Central America, the Caribbean, and Peru.


edit-20180630.jpg

These $2,000 solar panels pull clean drinking water out of the air, and they might be a solution to the global water crisis

The global water crisis has wreaked havoc on communities around the world, from homes in Flint, Michigan, to megacities like Tokyo and São Paulo. The United Nations estimated that 2.1 billion people live without safe drinking water in their homes — a situation with severe health implications that can also limit economic prosperity.

DSB-150107-2828.jpg

Why This Entrepreneur Ditched Fashion for the 'Hunting and Gathering' Business

The culmination of Duncan Berry's lifelong romance with the sea is available in more than 5,000 grocery stores around the country. Fishpeople Seafood, which employs close to 40 workers in-season, delivers for domestic consumption sustainable seafood caught in American waters by independent fisher folk. After 20 years of building fashion companies, Berry returned to the Oregon coast where he was raised.


Baby+Holding+Delivery+Tube_small.jpg

High-flow oxygen company Vapotherm inhales $56M in IPO

Respiratory care specialist Vapotherm raised $56 million in an initial public offering of 4 million shares, priced at the low end of the range at $14. The Exeter, New Hampshire-based company plans to list on the New York Stock Exchange under the ticker symbol VAPO. Vapotherm’s products deliver mask-free, high-flow oxygen support to hospital patients in respiratory distress, using nasal cannulae at volumes up to 8 L/m in infants or 40 L/m in adults, as an alternative to other pressure-based ventilation devices.

Web+Screen+Shot+1.jpg

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

SAN DIEGO – Sept. 9, 2019 – Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA)…


arch.jpg

Arch Oncology Raises $50 Million Series B Financing

BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.

Fishpeople.jpg

Eat Better Seafood: Easy New Way For You To Buy Delicious Fish

Two weeks ago the Dr. Oz Show did an episode entitled “Lies You Have Been Told About Your Salmon.” The show noted several problems, including the common scam of fraudulent labeling and selling farmed salmon as wild caught (43% of all salmon tested nationwide was mislabeled!) and substituting cheaper species for premium ones. “You take farm raised salmon and pass it off as chinook - the difference between those two can be upwards of $15 a pound,” noted guest expert Julia Collin Davison of America’s Test Kitchen.


Rubicon.jpg

Rubicon Global Recognized as a “Best For The World” B Corp for Sustainability and Environmental Excellence

Atlanta, GA (September 4, 2019) — Rubicon Global, a Certified B Corp, today announced the company has been named a Best For The World honoree in recognition of our environmental performance and sustainable business practices, ranking in the top 10% of all B Corps for our environmental responsibility. Rubicon Global is a technology company that powers a digital marketplace, provides a suite of SaaS products for waste, recycling, and smart city solutions, and collects and analyzes data for businesses and governments worldwide.

Smart Wires.jpg

Smart Wires and Hunt Energy Solutions Announce Distribution Partnership in Latin America

Smart Wires and Hunt Energy Solutions are pleased to announce their formal partnership whereby Hunt Energy Solutions will serve as Smart Wires’ exclusive distribution partner in the Latin American areas of Mexico, Central America, the Caribbean, and Peru. Smart Wires sees key strategic reasons to partner with Hunt Energy Solutions to accelerate commercial adoption by leveraging Hunt’s extensive connections in these Latin American markets.


Amplyx.jpg

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate, for treatment of cryptococcosis. Orphan drug designation qualifies APX001 for seven years of market exclusivity in the U.S. upon FDA approval of a new drug application (NDA) for the orphan designated indications. APX001 had previously received orphan drug designation for the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp., and Mucorales fungi (including Mucor spp., and Rhizopus spp.). In addition to orphan designations, FDA had previously granted Qualified Infectious Disease Product (QIDP) designation for APX001 for treatment of cryptococcosis, invasive candidiasis, invasive aspergillosis, and coccidioidomycosis. QIDP provides significant development incentives including eligibility for Fast Track designation, priority review and when combined with orphan drug designation, a total of twelve years of marketing exclusivity.

allakos.jpg

Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK) today announced positive results from its Phase 2 randomized, double-blind, placebo-controlled trial of AK002 in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis. All AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient reported disease symptoms. Statistically significant differences in patient symptoms between the active and placebo groups occurred one day following AK002 administration. In addition, patients with comorbid eosinophilic esophagitis treated with AK002 experienced statistically significant decreases in esophageal eosinophil counts and substantial reductions in patient reported dysphagia symptoms.


ZMW.jpg

These $2,000 solar panels pull clean drinking water out of the air, and they might be a solution to the global water crisis

The global water crisis has wreaked havoc on communities around the world, from homes in Flint, Michigan, to megacities like Tokyo and São Paulo. The United Nations estimated that 2.1 billion people live without safe drinking water in their homes — a situation with severe health implications that can also limit economic prosperity. Citizens with access to clean water have a better chance of escaping poverty, fending off disease, and pursuing an education. As the crisis escalates, many billionaire investors and tech companies have jumped at the chance to get involved. In September, a $1 billion fund led by Bill Gates, Jeff Bezos, and other investors helped finance the efforts of Zero Mass Water, a startup making solar panels that pull clean drinking water from the air. The panel arrays, known as Source, use sunlight to harvest water from air vapor. The harvested vapor is then sterilized and turned to liquid, which is stored in a reservoir that connects to your home faucet.

vapotherm.jpg

Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure (ADHF).


arch2.jpg

Arch Oncology to Present Preclinical Data on Highly-differentiated Anti-CD47 Antibody AO-176 at the AACR Annual Meeting 2019

BRISBANE, CA and ST. LOUIS, MO, March 29, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA. “We are excited to present these new sets of preclinical data at AACR, highlighting the progress our team is making with advancing our novel antibody programs,” said Julie M. Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology. “The most recent data on AO-176 build on the growing body of research showing that our highly differentiated anti-CD47 antibody selectively binds to and directly kills tumor cells while sparing normal cells. We will continue to work hard to advance AO-176in our ongoing Phase 1 clinical trial in patients with select solid tumors. In addition, we are presenting for the first time preclinical data from our novel, discovery-stage anti-SIRP antibody program.”